Publications and Presentations

Publications

Brown G et al. Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate. Frontiers in Veterinary Science, 26 October 2022
De Ridder T et al. Tigilanol Tiglate-Mediated Margins: A Comparison With Surgical Margins in Successful Treatment of Canine Mast Cell Tumours. Frontiers in Veterinary Science, 15 December 2021
Brown G et al. Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate. Frontiers in Veterinary Science, 27 August 2021
Reddell P et al. Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate. Journal of veterinary internal medicine, January 2021
Jones P et al. Recurrence‐free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate. Journal of veterinary internal medicine, December 2020
De Ridder T et al. Use of the intratumoural anticancer drug tigilanol tiglate in two horses. Frontiers in Veterinary Science, 09 September, 2020
De Ridder T et al. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC -46). Journal of Veterinary Internal Medicine, June 2020
Miller J et al. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors.. Frontiers in Veterinary Science, Volume 6, Article 106, April 2019
Barnett C, et al. Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate. Investigational New Drugs; April 2018
Campbell J, et al. Using triamcinolone in combination with the investigational anticancer agent EBC-46 (tigilanol tiglate) in the local treatment of a canine subcutaneous mast cell tumour. C&T No. 5598 2017
Boyle G, et al. Intra-lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models, PLOS ONE 2017, Vol 9, Issue 10, page number: e108887
Grant EL et al. Floral and reproductive biology of the medicinally significant rainforest tree, Fontainea picrosperma (Euphorbiaceae) Industrial Crops & Products 108 (2017) 416-422

Presentations

FDA-CVM WARNING: SEVERE WOUND FORMATION IN HUMANS; EXTENSIVE WOUND FORMATION, MAST CELL DEGRANULATION, AND DEATH IN DOGS DUE TO MAST CELL DEGRANULATION Human Safety

Accidental self-injection of STELFONTA^® may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary (see Dosage and Administration, Human Warnings and Adverse Reactions).

Dog Safety

Always administer a corticosteroid, an H1 receptor blocking agent (e.g. diphenhydramine), and an H2 receptor blocking agent (e.g. famotidine) when treating with STELFONTA to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation (see Contraindications and Dosage and Administration).
Do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock (e.g. on the body, head, or neck). This may result in accumulation of necrotic debris in the subcutaneous space increasing the risk of systemic adverse reactions, including death, from mast cell degranulation (see Contraindications, Warnings and Adverse Events).
Treatment with STELFONTA has been associated with cellulitis and severe tissue sloughing extending away from the treated site resulting in extensive wounds that require additional treatment and prolonged recovery times (see Warnings, Precautions and Adverse Events).

IMPORTANT SAFETY INFORMATION Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. Full prescribing information